The Analysis of Efficacy Factors for Autologous Platelet-Rich Plasma Therapy in the Treatment of Elbow Tendinopathy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Elbow Tendinopathy
Interventions
BIOLOGICAL

Autologous Platelet-Rich Plasma (PRP) Injection

Participants will receive autologous PRP injections prepared from their own blood to treat elbow tendinopathy. PRP is a plasma product with a 3-5 times higher platelet concentration than normal blood, containing growth factors such as TGF-β, PDGF, IGF, and EGF, which are known to promote tissue repair and regeneration. The PRP will be injected directly into the affected tendon area to evaluate its clinical effectiveness and the relationship between platelet concentration, growth factors, and treatment outcomes.

Trial Locations (1)

13496

Bundang CHA Medical Center, Seongnam-si

All Listed Sponsors
lead

CHA University

OTHER